Phase 2 ALK Gene Mutation trials recruiting now

All ALK Gene Mutation trials, every phase

Phase 2 ALK Gene Mutation trials

• A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib
  NCT06378892 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• Alectinib Pharmacokinetic in Patients With NSCLC
  NCT05713006 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK
  NCT05266846 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation
  NCT04322890 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location

Common questions

What does Phase 2 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.